The Breast Cancer Network Australia (BCNA) is celebrating the listing of Trodelvy, a treatment for a rare form of breast cancer on the Pharmaceutical Budget Listing (PBS) as part of the 2022/23 Federal Budget. “For the first time, this drug gives hope to many young women, extending their life expectancy and providing an opportunity to spend precious time with their loved ones,” Federal Treasurer Josh Frydenberg said on Mar. 29. The government is expected to invest $183.3 million (US$137.6 million) into the drug which is estimated to save on average, 580 patients $80,000 (US$60,052) per year for the treatment. The drug has been proven to extend the lives of people with inoperable or incurable breast cancer. The Therapeutic Goods Administration (TGA) approved Trodelvy for use in adults with inoperable locally advanced [in cancer progression] or metastatic triple-negative breast cancer who have received two or more prior therapies on Sep. 14, 2021. …